BIT Capital GmbH Makes New $1.12 Million Investment in MoonLake Immunotherapeutics (NASDAQ:MLTX)

BIT Capital GmbH acquired a new stake in MoonLake Immunotherapeutics (NASDAQ:MLTX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,748 shares of the company’s stock, valued at approximately $1,124,000.

Several other large investors also recently modified their holdings of the stock. KLP Kapitalforvaltning AS acquired a new position in MoonLake Immunotherapeutics in the 4th quarter valued at about $244,000. Barclays PLC boosted its holdings in shares of MoonLake Immunotherapeutics by 1,269.2% during the third quarter. Barclays PLC now owns 5,641 shares of the company’s stock worth $283,000 after acquiring an additional 5,229 shares during the period. Teacher Retirement System of Texas boosted its holdings in shares of MoonLake Immunotherapeutics by 18.4% during the fourth quarter. Teacher Retirement System of Texas now owns 6,532 shares of the company’s stock worth $354,000 after acquiring an additional 1,013 shares during the period. LPL Financial LLC grew its position in shares of MoonLake Immunotherapeutics by 19.5% in the fourth quarter. LPL Financial LLC now owns 8,146 shares of the company’s stock valued at $441,000 after purchasing an additional 1,332 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its stake in shares of MoonLake Immunotherapeutics by 3.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 8,500 shares of the company’s stock worth $460,000 after purchasing an additional 320 shares during the period. 93.85% of the stock is owned by institutional investors.

MoonLake Immunotherapeutics Stock Down 3.2 %

MLTX stock opened at $38.39 on Thursday. The company’s 50-day moving average price is $42.29 and its two-hundred day moving average price is $47.87. The firm has a market cap of $2.46 billion, a P/E ratio of -29.76 and a beta of 1.31. MoonLake Immunotherapeutics has a 12 month low of $36.52 and a 12 month high of $58.26.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.09). Equities analysts predict that MoonLake Immunotherapeutics will post -1.79 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on MLTX shares. Needham & Company LLC boosted their price target on MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. Royal Bank of Canada assumed coverage on shares of MoonLake Immunotherapeutics in a research report on Tuesday, March 18th. They issued an “outperform” rating and a $67.00 target price for the company. The Goldman Sachs Group lowered their price target on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. Finally, HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of MoonLake Immunotherapeutics in a report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $80.50.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.